Ion Exchange Chromatography for Teriparatide Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing teriparatide (PTH1-34) face challenges in separating the therapeutically active polypeptide from its variants and fragments, particularly PTH2-34, due to similar retention properties in ion exchange chromatography, leading to co-elution and reduced purity, which is critical for safety and efficacy.
Innovation Solution
A novel ion exchange chromatography method using inversely directed gradients of pH and ionic strength, specifically increasing pH and decreasing ionic strength, effectively separates PTH1-34 from its variants and fragments, such as PTH2-34, by eluting the polypeptide from a cation exchange material.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional ion exchange chromatography is used to purify PTH1-34, then the purification process is simple and established, but PTH1-34 co-elutes with PTH2-34 fragment resulting in reduced purity
Solution Approach 1:
The invention changes the elution parameters by using a decreasing salt gradient (reversing the conventional increasing gradient) to achieve differential elution of PTH1-34 and PTH2-34. This parameter reversal causes PTH2-34 to elute first followed by PTH1-34, resolving the co-elution problem and achieving high purity without requiring additional chromatography steps
Solution Approach 2:
The invention inverts the conventional elution approach by using a decreasing salt concentration gradient instead of an increasing one. This inversion of the gradient direction creates distinct elution profiles where the fragment PTH2-34 elutes before the full-length PTH1-34, thereby separating them effectively while maintaining method simplicity
2Manufacturing precision
If alternative chromatographic techniques such as reversed phase chromatography are used, then different separation mechanisms are applied, but they fail to achieve preparative separation of truncated and full-length teriparatide
Solution Approach 1:
The invention optimizes the ion exchange chromatography parameters specifically for preparative scale separation by using a decreasing salt gradient with controlled pH conditions. This parameter optimization enables effective separation of PTH1-34 from truncated fragments at preparative scales, achieving both high purity and productivity that alternative methods fail to deliver
3Manufacturing precision
If multiple chromatography steps are added to improve purification, then purity of PTH1-34 increases, but product loss increases and process complexity increases
Solution Approach 1:
By inverting the salt gradient direction, the invention achieves effective separation in a single chromatography step rather than requiring multiple steps. This inversion allows PTH2-34 to elute first, enabling collection of pure PTH1-34 in subsequent fractions without the need for additional purification steps, thereby minimizing product loss while maintaining high purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high purity of PTH1-34 with minimal product loss, effectively removing truncated and chemically modified variants, enhancing the safety and efficacy of the therapeutic product.
Implementation Method 1
purifying the PTH1-34 polypeptide by cation exchange chromatography
Implementation Method 2
eluting the polypeptide by increasing the pH and decreasing the ionic strength in the eluting fluid
Data Source
AI summary
The present invention relates to a novel method for purifying teriparatide, a therapeutically active polypeptide fragment of full-length human parathyroid hormone. The method is based on ion exchange chromatography and is effective in separating the therapeutically active polypeptide from undesirable variants, such as truncated polypeptides. The method of the invention can be used at a preparative scale which allows it to be implemented into the production process for teriparatide. Accordingly, the invention also provides a method for the production of teriparatide which includes a step in which teriparatide is purified by the novel ion exchange chromatography method of the invention.